2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

909. Medical Education and Workforce Development: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Women’s Health, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Genetic Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, CLL, Research, Clinical Research, Patient-Reported Outcomes, Study Population, Human
PAPER

4609 Online CME advances team-based integration of bispecific antibodies to optimize care of multiple myeloma in the community

Sarah Elizabeth Bomba, PharmD, BCOP, Haleh Kadkhoda, MS2, Megan Whitney, DMD3, Tristin Abair, PhD4, Andrew Small5, Jenna Parker6, S. Vincent Rajkumar, MD7
1 Medscape Education, Newark, New Jersey, United States
2 Medscape Education, Newark, New Jersey, United States
3 Medscape Education, Newark, New Jersey, United States
4 Medscape Education, Newark, New Jersey, United States
5 Medscape Education, Newark, New Jersey, United States
6 Medscape Education, Newark, New Jersey, United States
7 Mayo Clinic, Rochester, Minnesota, United States

Background: Bispecific antibodies represent a transformative therapeutic advancement for relapsed/refractory multiple myeloma (R/R MM). However, managing complex adverse events (AEs)—including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), dermatologic toxicities, and severe infections—presents ongoing challenges for care teams. As these immunotherapies transition into broader clinical practice, addressing persistent safety, knowledge, and competency gaps among community clinicians is essential to optimize patient care delivery.

Aim: To evaluate the impact of an interprofessional CME/CE initiative developed by Medscape Oncology, the International Myeloma Foundation (IMF) and a task force of community and academic clinicians to improve the knowledge, competency, and confidence of hematology/oncology specialists (Hem/Oncs) and advanced practice providers (NPs/PAs) of bispecific antibody toxicity management and team-based collaboration strategies.

Methods: This multi-phase initiative originated with a virtual community-academic clinician task force that identified key AE management challenges, resulting in a published summary. Findings directly informed a CME/CE-certified interprofessional roundtable discussion providing guidance on AE management. Educational impact was evaluated using a 4-question repeated-pair pre-/post Linked Learner Assessment (LLA) design measuring changes in knowledge, competency, and self-reported confidence. The activity launched online in January 2026, with outcomes measures collected through June 2026. Statistical significance was calculated using McNemar's test at the learning objective level and paired-samples t-tests (P < .05).

Results:  A total of N = 515 targeted clinicians participated, 80% of whom practiced in a non-academic/community setting (n = 189 Hem/Oncs; n = 326 NPs/PAs). These clinicians managed an average of 3.6 and 6.2 myeloma patients monthly, respectively. In total, N = 196 paired completers were included in the outcomes analysis.

Statistically significant pre-to-post improvements were observed across all learning themes:

Overall Knowledge & Competency Gains: Overall knowledge/competency improved in 51% of Hem/Oncs (mean score: 58% to 79%; 36% relative increase; P < .001) and 41% of NPs/PAs (31% to 47%; 52% relative increase; P < .001) Agent-Specific Toxicity Identification: Correct recognition of talquetamab associated palmar-plantar skin toxicity increased from 43% to 68% in Hem/Oncs (58% relative change; P < .001) and 19% to 34% in NPs/PAs (79% relative change; P < .001) Bispecific Antibody Safety Profiles: Understanding that low-grade CRS occurs with highest frequency during step-up dosing grew from 68% to 82% in Hem/Oncs (21% relative change; P < .01) and 50% to 60% in NPs/PAs (20% relative change; P < .01) Refractory Fever Management: Selecting return clinic evaluation and tocilizumab for steroid-refractory step-up fever rose from 61% to 82% in Hem/Oncs (34% relative change; P < .001) and 30% to 50% in NPs/PAs (67% relative change; P < .001) Infection Prophylaxis Strategies: Recommending prophylactic IVIG administration for ongoing bispecific therapy increased from 61% to 84% in Hem/Oncs (38% relative change; P < .001) and 24% to 45% in NPs/PAs (88% relative change; P < .001) Interprofessional Team Confidence: 32% of Hem/Oncs (mean shift: 2.46 to 2.89 on a 5-point scale) and 30% of NPs/PAs (mean shift: 1.87 to 2.23 on a 5-point scale) reported increased confidence in multidisciplinary collaboration.

Conclusions: This CME activity demonstrated the impact of targeted interprofessional education to enhance preparedness among clinicians caring for patients with R/R MM with bispecific antibodies. While Hem/Oncs demonstrated higher baseline familiarity with disease concepts, educational gains among NPs/PAs suggest that CME can help extend therapy-specific expertise across specialties involved in adverse event recognition and management. These findings highlight the role of targeted CME in strengthening interprofessional care pathways for R/R MM in community practice and support education-based strategies to facilitate earlier toxicity recognition, evidence-informed decision-making, and coordinated patient care.

Sarah Elizabeth Bomba, PharmD, BCOP: No relevant conflicts of interest to declare.